QIAGEN’s Post

View organization page for QIAGEN

289,291 followers

We exceeded our outlook and delivered a solid performance in Q3 2024. Learn more 👉 https://lnkd.in/eZ3CHdXZ   ◾ Q3 2024: Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS of $0.57.   ➡ Net sales of $502 million CER ahead of outlook for at least $495 million CER and adjusted diluted EPS of $0.58 CER ahead of outlook for at least $0.55 CER.   ➡ +10% CER growth in Diagnostic solutions leads results among product groups.   ➡ 29.6% adj. operating income margin up 3 percentage points vs. 26.6% in Q3 2023. ➡ Free cash flow up 73% to $364 million in first nine months of 2024 vs. same 2023 period.   ◾ FY 2024 net sales outlook reaffirmed for at least $1.985 billion CER on solid core business trends; adj. diluted EPS outlook increased to at least $2.19 CER.

  • No alternative text description for this image
Ruston Lievore

Médico Patologista Clínico na HEMOES

3mo

👍👍👏👏❤️❤️

Pankaj Dhar

Service Delivery | M&A | Transition | Project Management

3mo

Keep growing

Ravi Ranjan Kumar

Client Partner, Growth & Transformation Leader, Strategy, CXO advisory, Sales, Customer Centric, Design Thinker, INSEAD

3mo

Congratulations QIAGEN...

Felix Weber

Senior Key Account Manager of LRE Medical

3mo

Congrats!

See more comments

To view or add a comment, sign in

Explore topics